Editorial Commentary
New progress in early breast cancer treatment in 2021
Translational Breast Cancer Research
2022;
3:
20
(30 April 2022)
Case Report
Pseudoangiomatous stromal hyperplasia causing massive unilateral breast enlargement—a case report
Translational Breast Cancer Research
2022;
3:
19
(30 April 2022)
Review Article
Round table discussion: strategies for the treatment of HER2-positive advanced breast cancer in the rising age of antibody-drug conjugates
Translational Breast Cancer Research
2022;
3:
18
(30 April 2022)
Review Article
Narrative review of current status and recommendations in treatment for advanced triple-negative breast cancer
Translational Breast Cancer Research
2022;
3:
17
(30 April 2022)
Review Article
Narrative review of progress in pathological diagnosis of breast cancer
Translational Breast Cancer Research
2022;
3:
16
(30 April 2022)
Original Article
Efficacy and safety of inetetamab in combination with chemotherapy as first-line treatment of HER2-positive metastatic breast cancer: a subgroup analysis in the HOPES study
Translational Breast Cancer Research
2022;
3:
15
(30 April 2022)
Original Article
The study of correlation between nomogram prediction of uric acid and different chemotherapy regimens in breast cancer patients
Translational Breast Cancer Research
2022;
3:
14
(30 April 2022)
Guideline
Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
Translational Breast Cancer Research
2022;
3:
13
(30 April 2022)
Editorial
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guideline update: adjuvant therapy for triple negative breast cancer in 2022
Translational Breast Cancer Research
2022;
3:
12
(30 April 2022)
Editorial
Escalating and de-escalating treatments in HR+HER2− early-stage breast cancer
Translational Breast Cancer Research
2022;
3:
11
(30 April 2022)
Editorial
CDK4/6 inhibitors combined with fulvestrant for HR+/HER2− advanced breast cancer
Translational Breast Cancer Research
2022;
3:
10
(30 April 2022)
